The sponsors were not provided with a copy of this manuscript for review prior to submission, nor allowed input in the conduct or reporting of the work. The statements

in this paper are the authors’ and not those of their employers or the sponsors. The authors are or were employed by Exponent, a scientific and engineering selleck compound research and consulting firm, and have provided these services for private and government clients, including on projects involving arsenic. JST has presented on arsenic risk assessment issues in public comments to EPA and the NAS on behalf of industry and trade associations with interests in arsenic. JST has been retained in defense and plaintiff litigation cases related to arsenic. Transparency Document. The authors thank Betty Dowd, Mary Becker, Eileen McAuliffe, and Christine Shirley for graphics, editorial, and technical assistance. “
“En el artículo «Anemia ferropénica y uso de hierro endovenoso en patología digestiva» (Gastroenterol Hepatol.

2010;33[8]:605-613) de Fermín Mearin et al., se ha detectado un error en el nombre de uno de los autores. El see more nombre correcto es: Javier P. Gisbert. “
“Peripheral neuropathy is a common adverse effect of several classes of anti-cancer drugs, including vincristine, paclitaxel, oxaliplatin, cisplatin and bortezomib (Wolf et al., 2008). These agents exert direct and indirect effects on sensory nerves to reduce the amplitude of action potential, slow conduction velocity and induce pain in patients, especially those who experience

nociceptive sensory loss during treatment. Cancer chemotherapy-induced peripheral neuropathy (CIPN), which can selleck chemical be extremely painful, results in patient suffering and also limits the treatment with potentially useful anticancer drugs. The incidence of CIPN varies depending on the conditions with severe neuropathy (3–7%) with single agent, but can rise up to 38% with combination regimens (Connelly et al., 1996). Clinically, paclitaxel-induced neurotoxicity typically presents as a sensory neuropathy with the most common complaints being numbness, tingling and burning pain. The subjects mainly experience tingling and allodynia that often occur in a “glove and stocking” distribution. Sensory symptoms usually start symmetrically in the feet, but also appear simultaneously in both hands and feet (Dougherty et al., 2004). The most cases resolve within months after paclitaxel treatment is discontinued, but the sensory abnormalities and pain sometimes become a chronic problem (Rowinsky et al., 1993). The occurrence and severity of the neuropathy is dependent on many factors including single dose intensity, duration of infusion, cumulative dose, prior or concurrent treatment with cisplatin, and co-existing conditions such as diabetes and alcohol abuse. Oxaliplatin, a third-generation platinum-based chemotherapy drug, is a key drug in the treatment of colorectal cancer.